10 / 12
Page 46
Notes:
Journal of Infectious Diseases and Therapy ISSN: 2332-0877 | Volume: 6
Infectious Diseases
4
th
Annual Congress on
Neglected Tropical & Infectious Diseases
5
th
International Conference on
August 29-30, 2018 | Boston, USA
&
of Excellence in Vyskov in the Czech Republic. In his civilian position, he is at this moment developing withMT-Derm in Berlin
(Germany) a novel intradermal vaccination technology as well as a new therapy for cutaneous leishmaniasis for which he has
won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative blood separation
unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies
in Medicine and in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology,
immuno-hematology, infectious diseases, biodefense, and transfusion medicine. His natural business acumen and negotiation
competence help to initiate new successful businesses, often generated by unexpected combinations of technologies.
Biography
Dr. Stef Stienstra works internationally for several medical and biotech companies as the scientific advisory board member and is also an active reserve-officer
of the Royal Dutch Navy in his rank as Commander (OF4). For the Dutch Armed Forces, he is CBRN specialist with the focus on (micro)biological and chemical
threats and medical- and environmental functional specialist within the 1st CMI (Civil-Military Interaction) Battalion of the Dutch Armed Forces. For Expertise France
he is now managing an EU CBRN CoE public health project in West Africa. He is visiting professor for the University of Rome Tor Vergata in Italy for the CBRN
Masters Course and lecturer for the NATO School in Oberammergau in Germany and the Joint NATO CBRN-Defense Center of Excellence in Vyskov in the Czech
Republic. In his civilian position, he is at this moment developing with MT-Derm in Berlin (Germany) a novel intradermal vaccination technology as well as a new
therapy for cutaneous leishmaniasis for which he has won a Canadian ‘Grand Challenge’ grant. With Hemanua in Dublin (Ireland) he has developed an innovative
blood separation unit, which is also suitable to produce convalescent plasma for Ebola Virus Disease therapy. He has finished both his studies in Medicine and
in Biochemistry in The Netherlands with a doctorate and has extensive practical experience in cell biology, immuno-hematology, infectious diseases, biodefense,
and transfusion medicine. His natural business acumen and negotiation competence help to initiate new successful businesses, often generated by unexpected
combinations of technologies.
Stef.Stienstra@inter.nl.net